The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 2, 2001, Pages 782-792

  Lamprecht, Alf ^a,c,d   Ubrich, Nathalie ^b   Yamamoto, Hiromitsu ^c   Schäfer, Ulrich ^a   Takeuchi, Hirofumi ^c   Maincent, Philippe ^b   Kawashima, Yoshiaki ^c   Lehr, Claus Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITÉ DE LORRAINE   (France)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^d UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; CLOZAPINE; HALOPERIDOL; MUSCARINIC AGENT; NEUROLEPTIC AGENT; PILOCARPINE; SCOPOLAMINE; XANOMELINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONED REFLEX; CONTROLLED STUDY; DRUG MECHANISM; LOCOMOTION; MALE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; TRANQUILIZING ACTIVITY;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); CONFLICT (PSYCHOLOGY); DOPAMINE; EMOTIONS; HYPERKINESIS; MALE; MUSCARINIC AGONISTS; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; THIADIAZOLES;

EID: 0034761169     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade
2. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine
3. The so-called atypical antipsychotics-how similar are they?
4. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
5. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232)
6. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
7. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
8. Potential role of muscarinic receptors in schizophrenia
9. Neuroleptic antagonism of the motor inhibitory effects of apomorphine within the nucleus accumbens: Drug interaction at presynaptic receptors?
10. Neurochemical modulation of sensory-motor reactivity: Acoustic and tactile startle reflexes
11. Animal models of anxiety based on classical conditioning: The conditioned emotional response (CER) and the fear-potential startle
12. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain
13. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
14. Therapeutic opportunities for muscarinic receptors in the central nervous system
15. Cholinergic modulation of the acoustic startle response in the caudal pontine reticular nucleus of the rat
16. The effects of M100907 in pharmacological and developmental animal models of pre-pulse inhibition deficits in schizophrenia
17. Facilitation of amphetamine-induced rotation by muscarinic antagonists is correlated with M2 receptor affinity
18. Cholinesterase inhibition in Parkinson's disease
19. Adverse effects of anticholinergic medication on positive schizophrenic symptoms
20. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex
21. Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats
22. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease
23. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: A comparison of acute clozapine and haloperidol
24. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
25. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule
26. Sernyl, ditran, and their antagonists: Succinate and THA
27. Ditran and its antagonists in a mixed psychiatric population
28. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen
29. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex
30. Pilocarpine reversal of d-amphetamine induced increase in mouse exploratory locomotor activity
31. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
32. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors
33. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats
34. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor aganist, produces antipsychotic-like activity in rats and mice
35. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
36. 1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat
37. Olanzapine in the treatment of psychiatric disturbances associated with Alzheimer's disease
38. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
39. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs
40. 2 receptors